Scholar Rock Resubmits BLA for Apitegromab in SMA Treatment Scholar Rock has announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for apitegromab, an investigational therapy intended for the treatment of children…
AN2 Therapeutics Initiates Phase 2 Trial of Epetraborole for Difficult-to-Treat M. abscessus Lung Disease AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies using its proprietary boron chemistry platform, has announced the initiation of a…
Emerging biotech advances novel platform to target previously “undruggable” epigenetic protein interfaces, aiming to develop precision therapies for pediatric brain cancers like DIPG TippingPoint Biosciences, an emerging player in the biotechnology sector, is positioning itself at the forefront of next-generation…
New ACC.26 Data Strengthen Evidence for Vutrisiran in ATTR-CM and Highlight Zilebesiran’s Potential in Hypertension Alnylam Pharmaceuticals, a leader in RNA interference (RNAi) therapeutics, announced new clinical and real-world findings from its cardiovascular portfolio at the American College of Cardiology’s…
PepGen Reports Positive Topline Results from Lowest-Dose (5 mg/kg) MAD Cohort in Phase 2 FREEDOM2 Study, Highlighting Safety, Splicing, and vHOT Outcomes PepGen has reported encouraging topline results from the lowest-dose cohort (5 mg/kg) in its ongoing Phase 2 FREEDOM2…
Eight Hospitals Earn National Recognition as Investments Enhance Care, Expand Services, and Strengthen Workforce One year after entering the Illinois healthcare landscape, Prime Healthcare and the Prime Healthcare Foundation have marked a significant milestone with more than $104 million invested…
DiaMedica Therapeutics Reports Full-Year 2025 Financial Results and Highlights Clinical Progress DiaMedica Therapeutics a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious conditions such as preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS), has announced…
Organigram Shareholders Approve Sanity Group Acquisition and Key Resolutions at 2026 Annual Meeting Organigram Global has announced that its shareholders have overwhelmingly approved the company’s previously disclosed acquisition of Sanity Group GmbH, along with several other important resolutions, during its…
TruBridge Delays Reporting to Complete Year-End Audit, Sets New Earnings Release and Call Schedule TruBridge, Inc. has announced a revised schedule for the release of its financial results for the fourth quarter and full year ending December 31, 2025, along…
Emmaus Life Sciences Announces Full-Year 2025 Financial Results Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company focused on treatments for sickle cell disease, has reported its financial condition and operating results for the year ended December 31, 2025. The company’s…
Canopy Growth Corporation’s Apollo Cannabis Clinics Earn Top Honor in 2025 Toronto Star Readers’ Choice Awards SMITH FALLS, Ontario—Canopy Growth Corporation (“Canopy Growth” or “the Company”) has announced that its healthcare arm, Apollo Cannabis Clinics (“Apollo”), has been named Best…
Sensei Biotherapeutics Reports Full-Year 2025 Results, Advances PIKTOR Following Faeth Acquisition and $200 Million Financing Sensei Biotherapeutics, has reported its financial results for the full year ended December 31, 2025, while also providing a comprehensive corporate update highlighting major strategic…